Mucocutaneous lichen planus with esophageal involvement: Successful treatment with an anti-CD20 monoclonal antibody

Archives of Dermatology

Volumn 144, Issue 11, 2008, Pages 1427-1430

  Parmentier, Laurent ^a,c,d   Bron, Blaise Alain ^b   Prins, Christa ^a   Samson, Jacky ^a   Masouyé, Isabelle ^a   Borradori, Luca ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Médecin Gastro Entérologue   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d HÔTEL DIEU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CORTICOSTEROID; METHYLPREDNISOLONE; TACROLIMUS;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; ESOPHAGOSCOPY; ESOPHAGUS INJURY; FEMALE; HISTOPATHOLOGY; HUMAN; LICHEN PLANUS; MUCOCUTANEOUS LICHEN PLANUS; PRIORITY JOURNAL; SKIN EXAMINATION;

ANTIBODIES, MONOCLONAL; BIOPSY, NEEDLE; DEGLUTITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ESOPHAGEAL DISEASES; ESOPHAGOSCOPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LICHEN PLANUS; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 56549085253     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archderm.144.11.1427     Document Type: Article

References (20)

1. Keate RF, Williams JW, Connolly SM. Lichen planus esophagitis: report of three patients treated with oral tacrolimus or intraesophageal corticosteroid injections or both. Dis Esophagus. 2003;16(1):47-53.
2. Bobadilla J, van der Hulst RW, ten Kate FJ, Tytgat GN. Esophageal lichen planus. Gastrointest Endosc. 1999;50(2):268-271.
3. Jobard-Drobacheff C, Blanc D, Quencez E, et al. Lichen planus of the oesophagus. Clin Exp Dermatol. 1988;13(1):38-41.
4. + follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;137(3):269-272.
5. Joly P, Mouquet H, Roujeau JC, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357(6):545-552.
6. Hertl M, Eming R, Borradori L. Rituximab (anti-CD20 monoclonal antibody) - ultimate or first choice in pemphigus? Dermatology. 2007;214(4):275-277.
7. Aractingi S, Chosidow O. Cutaneous graft-versus-host disease. Arch Dermatol. 1998;134(5):602-612.
8. Sato M, Tokuda N, Fukumoto T, Mano T, Sato T, Ueyama Y. Immunohistopathological study of the oral lichenoid lesions of chronic GVHD. J Oral Pathol Med. 2006;35(1):33-36.
9. Zaja F, Bacigalupo A, Patriarca F, et al. GITMO (Gruppo Italiano Trapianto Midollo Osseo): treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40(3):273-277.
10. Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9(8):505-511.
11. Eisenberg R, Albert D. B-cell targeted therapies in rheumatoid arthritis and systemic lupus erythematosus. Nat Clin Pract Rheumatol. 2006;2(1):20-27.
12. Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143(6):763-767.
13. Abraham SC, Ravich WJ, Anhalt GJ, Yardley JH, Wu TT. Esophageal lichen planus: case report and review of the literature. Am J Surg Pathol. 2000;24(12):1678-1682.
14. Cheng A, Mann C. Oral erosive lichen planus treated with efalizumab. Arch Dermatol. 2006;142(6):680-682.
15. Böhm M, Luger TA. Lichen planus responding to efalizumab. J Am Acad Dermatol. 2007;56(5)(suppl):S92-S93.
16. Heffernan MP, Smith DI, Bentley D, Tabacchi M, Graves JE. A single-center, open-label, prospective pilot study of subcutaneous efalizumab for oral erosive lichen planus. J Drugs Dermatol. 2007;6(3):310-314.
17. Rebora A, Parodi A, Murialdo G. Basiliximab is effective for erosive lichen planus. Arch Dermatol. 2002;138(8):1100-1101.
18. Atzeni F, Doria A, Maurizio T, Sarzi-Puttini P. What is the role of rituximab in the treatment of rheumatoid arthritis? Autoimmun Rev. 2007;6(8):553-558.
19. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007;110(8):2924-2930.
20. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther. 2006;8(3):R83.